Cost-effectiveness of rosiglitazone monotherapy compared with glibenclamide monotherapy for treating Type 2 diabetes

被引：0
|
作者：
Beale, S [1 ]
Bagust, A [1 ]
Downs, KE [1 ]
Perry, AS [1 ]
机构：
[1] Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England
来源：
DIABETOLOGIA | 2002年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
932
引用
收藏
页码：A301 / A301
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of rosiglitazone monotherapy compared with glyburide monotherapy for treating type 2 diabetes
    Beale, S
    Bagust, A
    Downs, KE
    Perry, AS
    DIABETES, 2002, 51 : A270 - A270
  • [2] Rosiglitazone monotherapy and Type 2 diabetes
    Lawrence, IG
    DIABETIC MEDICINE, 2001, 5 : 6 - 8
  • [3] Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
    Gu, Shuyan
    Mu, Yiming
    Zhai, Suodi
    Zeng, Yuhang
    Zhen, Xuemei
    Dong, Hengjin
    PLOS ONE, 2016, 11 (11):
  • [4] Rosiglitazone monotherapy is effective in patients with type 2 diabetes
    Lebovitz, HE
    Dole, JF
    Patwardhan, R
    Rappaport, EB
    Freed, MI
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01): : 280 - 288
  • [5] Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy
    Raz, I
    Mouritzen, U
    Vaz, J
    Hershkovitz, T
    Wainstein, J
    Harman-Boehm, I
    CLINICAL THERAPEUTICS, 2003, 25 (12) : 3109 - 3123
  • [6] ASSESSING COST-EFFECTIVENESS OF ANTIMICROBIAL TREATMENT - MONOTHERAPY COMPARED WITH COMBINATION THERAPY
    DAVEY, PG
    VACANI, P
    PARKER, SE
    MALEK, MM
    EUROPEAN JOURNAL OF SURGERY, 1994, : 67 - 72
  • [7] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN VERSUS GLIMEPIRIDE AS MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CHINA
    Shao, H.
    Shi, L.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
  • [8] Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus
    Shao, Hui
    Zhai, Suodi
    Zou, Dajin
    Mir, Mohammed Umer
    Zawadzki, Nadine K.
    Shi, Qian
    Liu, Shuqian
    Shi, Lizheng
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (02) : 359 - 369
  • [9] Benefits beyond glycaemia of adding rosiglitazone rather than glibenclamide to metformin monotherapy in Type 2 diabetes mellitus.
    Cobitz, A
    Ryan, C
    Rood, J
    Waterhouse, B
    Strachan, M
    DIABETOLOGIA, 2003, 46 : A289 - A289
  • [10] Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy
    Garber, A
    Klein, E
    Bruce, S
    Sankoh, S
    Mohideen, P
    DIABETES OBESITY & METABOLISM, 2006, 8 (02): : 156 - 163
12345